Diplomat Pharmacy (NYSE: DPLO) continues to diversify away from being just a traditional specialty pharmacy, announcing the acquisition of National Pharmaceutical Services, a pharmacy benefit manager, in conjunction with its third-quarter earnings. Previous additions of specialty infusion and pharma services have already worked their way into the company’s earnings, making up more than half of the company’s EBITDA.
Metric
Q3 2017